New warning information for ADHD drugs

Share this article:
Two attention deficit hyperactivity disorder (ADHD) drugs must include new information about heart risks and psychotic behavior, the FDA said yesterday. GlaxoSmithKline’s Dexedrine and Novartis’ Ritalin will include a warning about the possible risk of sudden death and serious heart problems, Reuters reported. At press time it was unclear whether ADHD drugs from Johnson & Johnson's (Concerta) and Eli Lilly (Strattera) were also ordered to carry the warnings. The FDA's decision comes months after two separate panels of outside experts offered conflicting opinions on whether the risks warranted black box warnings.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions